2. Cytoskeleton
  3. Integrin
  4. Arg-Gly-Asp-Ser

RGDS peptide  (Synonyms: Arg-Gly-Asp-Ser; Fibronectin tetrapeptide)

製品番号: HY-12290 純度: 98.70%
COA 取扱説明書 Technical Support

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

Arg-Gly-Asp-Ser

RGDS peptide 構造式

CAS 番号 : 91037-65-9

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 41 在庫あり
Solution
10 mM * 1 mL in DMSO USD 41 在庫あり
Solid
5 mg $38 在庫あり
10 mg $61 在庫あり
50 mg $193 在庫あり
100 mg $347 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

Other Forms of Arg-Gly-Asp-Ser:

RGDS peptide 関連抗体

Top Publications Citing Use of Products

Integrin アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

  • 生物活性

  • プロトコル

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

Cellular Effect
Cell Line Type Value Description References
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
[PMID: 23757209]
HUVEC IC50
22.7 3
Compound: RGDS
Inhibition of HUVEC adhesion to fibrinogen-coated plates
Inhibition of HUVEC adhesion to fibrinogen-coated plates
[PMID: 9651154]
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
[PMID: 21852128]
HUVEC IC50
3.5 3
Compound: RGDS
Inhibition of HUVEC adhesion to fibrinogen-coated plates
Inhibition of HUVEC adhesion to fibrinogen-coated plates
[PMID: 9651154]
HUVEC IC50
> 250 3
Compound: RGDS
Inhibition of HUVEC adhesion to fibrinogen-coated plates
Inhibition of HUVEC adhesion to fibrinogen-coated plates
[PMID: 9651154]
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
[PMID: 23757209]
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
[PMID: 21852128]
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma by Borns method
[PMID: 21852128]
Platelet IC50
31 3
Compound: RGDS
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method
[PMID: 23757209]
体外実験

The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3?integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited[1].
Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (Kd 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RGDS peptide 関連抗体
体内実験

Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS[2].
Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

433.42

分子式

C15H27N7O8
CAS 番号
Appearance

Solid

Color

White to off-white

Sequence

Arg-Gly-Asp-Ser
Sequence Shortening

RGDS
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 50 mg/mL (115.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 25 mg/mL (57.68 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3072 mL 11.5362 mL 23.0723 mL
5 mM 0.4614 mL 2.3072 mL 4.6145 mL
10 mM 0.2307 mL 1.1536 mL 2.3072 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
純度とドキュメンテーション

純度: 98.70%

COA (246 KB) RP-HPLC (255 KB) MS (69 KB)

取扱説明書 (2659 KB)
参考文献
細胞実験
[1]

Cell death is measured using the MTT analysis. This assay is based on the ability of mitochondrial dehydrogenases to oxidize thiazolyl blue (MTT), a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide), to an insoluble blue formazan product. The cells are incubated with the MTT reagent (120 μg/mL) at 37°C for 2 h. After the supernatant is removed, 400 μL of 0.04mol/LHCl in isopropanol is added to each well, and the optical density of the solution is read at 590 nm in an enzyme-linked immunosorbent assay plate reader. As the generation of the blue product is proportional to the dehydrogenase activity, a decrease in the absorbance at 590 nm provides a direct measurement of the number of viable cells. To determine the contribution of the PI3K pathway to inhibition of apoptosis, some cell populations are pretreated with 50 μM LY294002, a PI3K inhibitor. Following this pretreatment, cell death is determined as described above.

MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
動物実験
[2]

Mice pharyngeal aspiration is performed as described. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with Arg-Gly-Asp-Ser or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered Arg-Gly-Asp-Ser or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS

MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 2.3072 mL 11.5362 mL 23.0723 mL 57.6808 mL
5 mM 0.4614 mL 2.3072 mL 4.6145 mL 11.5362 mL
10 mM 0.2307 mL 1.1536 mL 2.3072 mL 5.7681 mL
15 mM 0.1538 mL 0.7691 mL 1.5382 mL 3.8454 mL
20 mM 0.1154 mL 0.5768 mL 1.1536 mL 2.8840 mL
25 mM 0.0923 mL 0.4614 mL 0.9229 mL 2.3072 mL
30 mM 0.0769 mL 0.3845 mL 0.7691 mL 1.9227 mL
40 mM 0.0577 mL 0.2884 mL 0.5768 mL 1.4420 mL
50 mM 0.0461 mL 0.2307 mL 0.4614 mL 1.1536 mL
DMSO 60 mM 0.0385 mL 0.1923 mL 0.3845 mL 0.9613 mL
80 mM 0.0288 mL 0.1442 mL 0.2884 mL 0.7210 mL
100 mM 0.0231 mL 0.1154 mL 0.2307 mL 0.5768 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Arg-Gly-Asp-Ser Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Arg-Gly-Asp-Ser91037-65-9RGDS peptide Fibronectin tetrapeptideIntegrinInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Arg-Gly-Asp-Ser
製品番号:
HY-12290
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.